Why the study?
Does the C-reactive protein/albumin ratio (CAR) predict mortality better than CRP or albumin alone in patients with STEMI treated with PCI?
Does the C-reactive protein/albumin ratio (CAR) predict mortality better than CRP or albumin alone in patients with STEMI treated with PCI?
The C-reactive protein/albumin ratio serves as a superior prognostic marker compared to individual CRP or albumin levels for predicting mortality in STEMI patients undergoing PCI.
CAR may refine mortality risk stratification after STEMI-PCI; leaves open prospective validation versus CRP or albumin alone.
Serum C-reactive protein (CRP)/albumin ratio (CAR) is demonstrated as a more precise marker in determining the prognosis of critical diseases than albumin and CRP levels, separately. Recently, inflammatory biomarkers are increasingly used for both screening and prognosis of coronary artery disease (CAD). As an ischemia-dependent risk index, CAR is an independent marker of in-hospital and long-term all-cause mortality in ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention. The results indicate that CAR is a more effective prognostic marker than either CRP or albumin.
No takes yet. Share an insight, caveat, or question.
Aşkın et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: